Table 1:

Demographic, clinical, and white matter hyperintensity characteristics between patients with Parkinson disease with and without mild cognitive impairment

Demographic and Clinical VariablesPD-NCI (n = 65)PD-MCI (n = 25)P Value
Age (yr) (mean) (SD)63.4 (7.6)69.4 (6.4).001a,b
Sex (male) (No.) (%)46 (72.3)18 (76.0).723c
Education (yr) (mean) (SD)11.0 (3.1)9.3 (3.5).032a,d
Hoehn and Yahr (mean) (SD)1.9 (0.4)1.8 (0.4).357d
Disease duration (yr) (mean) (SD)5.4 (4.3)5.0 (2.7).910d
UPDRS (mean) (SD)17.5 (7.0)20.0 (8.4).167b
Levodopa equivalent dose (mg) (mean) (SD)557.4 (375.7)510.2 (299.0).767d
Cardiovascular risk factors (No.) (%)
    Diabetes5 (7.8)8 (32.0).004a,c
    Hypertension20 (31.3)13 (52.0).069c
    Hyperlipidemia20 (31.3)14 (56.0).031a,c
    Smoking15 (23.4)6 (24.0).955c
White matter hyperintensities
    Total WMH volume (mm) (mean) (SD)4.2 (5.8)12.3 (10.3)<.001a,e

  • Note:—UPDRS indicates Unified Parkinson's Disease Rating Scale, subscore III; WMH, white matter hyperintensities.

  • ↵a Significant differences at P < .05 level.

  • ↵b Student t test.

  • ↵c χ2 test.

  • ↵d Mann-Whitney U test.

  • ↵e Analysis of covariance test, corrected for age, sex, and education.